Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials

Tammenmaa, I. A., Sailas, E., McGrath, J. J., Soares-Weiser, K. and Wahlbeck, K. (2004) Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Progress In Neuro-psychopharmacology & Biological Psychiatry, 28 7: 1099-1107. doi:10.1016/j.pnpbp.2004.05.045


Author Tammenmaa, I. A.
Sailas, E.
McGrath, J. J.
Soares-Weiser, K.
Wahlbeck, K.
Title Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials
Journal name Progress In Neuro-psychopharmacology & Biological Psychiatry   Check publisher's open access policy
ISSN 0278-5846
Publication date 2004-01-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.pnpbp.2004.05.045
Volume 28
Issue 7
Start page 1099
End page 1107
Total pages 9
Editor P. J. Bedard
Place of publication USA
Publisher Elsevier Inc
Collection year 2004
Language eng
Subject C1
321021 Psychiatry
730211 Mental health
Abstract The authors evaluated the efficacy of cholinergic drugs in the treatment of neuroleptic-induced tardive dyskinesia (TD) by a systematic review of the literature on the following agents: choline, lecithin, physostigmine, tacrine, 7-methoxyacridine, ipidacrine, galantamine, donepezil, rivastigmine, eptastigmine, metrifonate, arecoline, RS 86, xanomeline, cevimeline, deanol, and meclofenoxate. All relevant randomized controlled trials, without any language or year limitations, were obtained from the Cochrane Schizophrenia Group's Register of Trials. Trials were classified according to their methodological quality. For binary and continuous data, relative risks (RR) and weighted or standardized mean differences (SMD) were calculated, respectively. Eleven trials with a total of 261 randomized patients were included in the meta-analysis. Cholinergic drugs showed a minor trend for improvement of tardive dyskinesia symptoms, but results were not statistically significant (RR 0.84, 95% confidence interval (CI) 0.68 to 1.04, p=0.11). Despite an extensive search of the literature, eligible data for the meta-analysis were few and no results reached statistical significance. In conclusion, we found no evidence to support administration of the old cholinergic agents lecithin, deanol, and meclofenoxate to patients with tardive dyskinesia. In addition, two trials were found on novel cholinergic Alzheimer drugs in tardive dyskinesia, one of which was ongoing. Further investigation of the clinical effects of novel cholinergic agents in tardive dyskinesia is warranted. (C) 2004 Elsevier Inc. All rights reserved.
Keyword Clinical Neurology
Neurosciences
Pharmacology & Pharmacy
Psychiatry
Cholinergic Agents
Drug-induced
Dyskinesia
Meta-analysis
Treatment Outcome
Alzheimers-disease
Oral Dyskinesias
Deanol
Haloperidol
Crossover
Therapy
Placebo
Pathophysiology
Schizophrenia
Enhancement
Q-Index Code C1

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: 2005 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 20 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 32 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 15:16:14 EST